Understanding ASH on All Myeloma Levels with Dr. Peter Voorhees
The American Society of Hematology (ASH) annual conference is a big deal in myeloma. Specialists gather and share newly published research and data. However, it can get difficult to keep track of everything that is shared. Dr. Peter Voorhees, myeloma specialist in Levine (North Carolina) is coming to the SouthEast to share what you need to know, regardless of where you are in your myeloma journey. What should precursor patients know about what was released? Do newly diagnosed patients have any new options? Any updates about maintenance therapy? And what options are released for those who are relapsed?
Dr. Voorhees shares what you need to know, regardless of where you are in your myeloma journey.
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Peter Voorhees, MD
Peter Voorhees, MD, is Director of Outreach and Clinical Operations for Hematologic Malignancies and a Member of the Plasma Cells Disorder Program at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees is an internationally recognized thought leader in multiple myeloma whose research focuses on the clinical development of novel therapeutic strategies for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. He is board certified in Hematology and a member of the American Society of Hematology, American Society of Clinical Oncology and International Myeloma Working Group. He is also a member of the Multiple Myeloma Committee of the Alliance Cooperative Group. He has published numerous original articles, reviews and book chapters in multiple myeloma. He received his medical degree from the University of Michigan, continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and completed a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Prior to joining the Levine Cancer Institute, he was an Associate Professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill where he led their Multiple Myeloma Program.